Conclusions: One year of pemafibrate therapy improves markers of hepatic inflammation, function, and fibrosis in NAFLD patients in whom long-term SGLT2 inhibitor therapy failed to normalize serum ALT. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.